Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30692909 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL19798188 | 0.78 | KDM4E (0.40) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL31727717 | 0.78 | KDM4E (0.40) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL29672973 | 0.78 | KDM4E (0.40) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL11041531 | 0.78 | KDM4E (0.36) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL23500465 | 0.78 | ALDH1A1 (0.36) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL3360364 | 0.78 | KDM4E (0.36) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL14783084 | 0.78 | KDM4E (0.40) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL20899365 | 0.78 | KDM4E (0.36) | ALDH1A1KDM4EPOLBLRRK2KMO | |
| SCHEMBL26331236 | 0.78 | CSNK1A1 (0.37) | ALDH1A1KDM4EPOLBLRRK2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20250243164-A1 | PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACID | AKEBIA THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| EP-3848370-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-12269802-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid | AKEBIA THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371562-A2 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158354-A1 | Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid | KREOS CAPITAL VII (UK) LIMITED (GB) | 2024-05-16 | — | — | US | disclosed |
| CN-117417923-A | Nitrilase mutant and application thereof | 浙江工业大学 | 2024-01-19 | — | — | CN | disclosed |
| EP-3630749-B1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-01-10 | — | — | EP | disclosed |
| US-11713298-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | AKEBIA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| WO-2013033981-A1 | 2,7-NAPHTHYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏先声药物研究有限公司 (CN) | 2013-03-14 | — | — | WO | disclosed |
| CN-102712636-A | Compounds and compositions as TLR activity modulators | IRM LLC | 2012-10-03 | — | — | CN | disclosed |
| WO-2012103044-A1 | PROCESS FOR THE PREPARATION OF 4-AMINO-3-CHLORO-5-FLUORO-6-(SUBSTITUTED)PICOLINATES | DOW AGROSCIENCES LLC (US) | 2012-08-02 | — | — | WO | disclosed |
| EP-2268618-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009111337-A1 | COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS | IRM LLC (BM) | 2009-09-11 | — | — | WO | disclosed |
| EP-0795541-B1 | Method for production of nuclear halogenated aromatic compound possessing cyano groups | NIPPON CATALYTIC CHEM IND (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-6034264-A | VAPOR PHASE REACTION; USING ACTIVATED CARBON AS CATALYST | NIPPON SHOKUBAI CO., LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| US-5789582-A | HALOGENATING CYANOAROMATIC COMPOUNDS IN THE VAPOR PHASE | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0795541-A1 | Method for production of nuclear halogenated aromatic compound possessing cyano groups | NIPPON SHOKUBAI CO., LTD. (JP) | 1997-09-17 | — | — | EP | disclosed |
| US-4766219-A | Preparation of 2-cyano-6-chloropyridine compounds | THE DOW CHEMICAL COMPANY (US) | 1988-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243164-A1 | PROCESS FOR PREPARING 2-[[5-(3-CHLOROPHENYL)-3-HYDROXYPYRIDINE-2-CARBONYL]AMINO]ACETIC ACID | AASDHPPT, AADAT, HPD | ALDH1A1 39/4885KDM4E 1427/4885POLB 2556/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALDH1A1 3157/4885KDM4E 738/4885POLB 4589/4885 |
| US-11713298-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid | AASDHPPT, AADAT, ALDH7A1 | ALDH1A1 15/4885KDM4E 1837/4885POLB 2135/4885 |
| US-20240158354-A1 | Process for Preparing 2-[[5-(3-Chlorophenyl)-3-Hydroxypyridine-2-Carbonyl]Amino]Acetic Acid | AASDHPPT, AADAT, ALDH7A1 | ALDH1A1 15/4885KDM4E 1837/4885POLB 2135/4885 |
| US-12269802-B2 | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino] acetic acid | AASDHPPT, AADAT, ALDH7A1 | ALDH1A1 15/4885KDM4E 1837/4885POLB 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.